|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1996-8-8
|
|
pubmed:abstractText |
Although serotonin reuptake inhibitors (SRIs) are the mainstay of pharmacologic treatment for obsessive-compulsive disorder (OCD), many patients do not have an adequate response to these medications. One approach to treating SRI-refractory OCD patients has been to add other classes of medications to the SRI. We predicted that augmentation with risperidone would alleviate symptoms in SRI-refractory OCD patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0160-6689
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
303-6
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8666572-Adult,
pubmed-meshheading:8666572-Akathisia, Drug-Induced,
pubmed-meshheading:8666572-Comorbidity,
pubmed-meshheading:8666572-Drug Therapy, Combination,
pubmed-meshheading:8666572-Female,
pubmed-meshheading:8666572-Humans,
pubmed-meshheading:8666572-Male,
pubmed-meshheading:8666572-Middle Aged,
pubmed-meshheading:8666572-Obsessive-Compulsive Disorder,
pubmed-meshheading:8666572-Psychiatric Status Rating Scales,
pubmed-meshheading:8666572-Risperidone,
pubmed-meshheading:8666572-Serotonin Uptake Inhibitors,
pubmed-meshheading:8666572-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
|
|
pubmed:affiliation |
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
